Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission

NEJM, 10 January 2018
Authors: Steven Joffe, Holly Fernandez Lynch
“Though popular with the public and supported by politicians from both parties, the legislation has been widely criticized by policy experts. In isolation, its impact would probably be limited, since the bill was substantially hollowed out to secure the necessary votes. Nonetheless, the motivation behind the proposed legislation threatens to weaken the FDA’s ability to pursue its public health mission.”
Find article here.

Makers of Nurofen ran ‘misleading and deceptive’ campaign against Panadol: court

SMH, 11 January 2018
Author: Stephanie Gardiner
“Nurofen is better than paracetamol for common headaches,” declared the advertisements in women’s lifestyle magazines. The Federal Court has found that claim to be misleading and deceptive, after two pharmaceutical giants went head-to-head in a two-year legal battle.”
Find article here.

Karimi v Medical Council of New South Wales

Decision date: 20 December 2017
“OCCUPATIONS – medical practitioners – suspension of registration under s 150 of the Health Practitioner Regulation National Law – external appeal under s 159 – nature of external appeal – allegations of professional misconduct, illegal prescribing, dispensing and storing of medication, inappropriate clinical record keeping, doctoring certificate and practising whilst unregistered – whether it is appropriate to terminate, vary or confirm period of suspension – period of suspension confirmed.”
Find decision here.